Is BiomX Inc. (PHGE) Halal?

NYSE Healthcare United States $7M
✗ NOT HALAL
Confidence: 90/100
BiomX Inc. (PHGE) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 88.3% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. BiomX Inc. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 88.3%
/ 30%
155.3%
/ 30%
10.8%
/ 30%
N/A ✗ NOT HALAL
DJIM 88.3%
/ 33%
155.3%
/ 33%
10.8%
/ 33%
N/A ✗ NOT HALAL
MSCI 22.2%
/ 33%
39.0%
/ 33%
2.7%
/ 33%
N/A ✗ NOT HALAL
S&P 88.3%
/ 33%
155.3%
/ 33%
10.8%
/ 33%
N/A ✗ NOT HALAL
FTSE 22.2%
/ 33%
39.0%
/ 33%
2.7%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-37.05
P/B Ratio
-0.4
EV/EBITDA
-0.8
EV: $23M
Revenue
$0
Beta
1.7
High volatility
Current Ratio
0.9

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -316.9%
Return on Assets (ROA) -78.9%

Cash Flow & Balance Sheet

Operating Cash Flow-$37M
Free Cash Flow-$37M
Total Debt$10M
Current Ratio0.9
Total Assets$43M

Price & Trading

Last Close$4.71
50-Day MA$5.18
200-Day MA$7.06
Avg Volume1.0M
Beta1.7
52-Week Range
$1.50
$14.71

About BiomX Inc. (PHGE)

CEO
Mr. Michael Oster
Employees
20
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NYSE
Market Cap
$7M
Currency
USD

BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is BiomX Inc. (PHGE) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), BiomX Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is BiomX Inc.'s debt ratio?

BiomX Inc.'s debt ratio is 88.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 22.2%.

What are BiomX Inc.'s key financial metrics?

BiomX Inc. has a market capitalization of $7M. Return on equity stands at -316.9%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.